About Qantgene
Qantgene is a Healthcare company based in Berkeley (United States) founded in 2015. Cancer screening blood tests are offered for early disease detection. Qantgene has raised $12.13 million across 3 funding rounds from investors including Vikor Scientific. Qantgene offers products and services including Qx, Genomic Tumor Profiling, and Qx Plus. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Quantgene Inc. Its competitors include GRAIL, Color and Earli; 3 of its 3 listed competitors have raised funding.
Company details
Qantgene was founded in 2015 and is based in Berkeley, United States, within the biotechnology sector. Blood tests for cancer screening and early disease detection are developed and provided. The GRIFFIN Deep Genomics platform is employed, integrating precision sequencing, software, and AI to analyze cell-free DNA fragments. Operations focus on profiling genetic material to support diagnostic applications in healthcare.
- Headquarters Berkeley, United States
- SectorsHealthcare
- Email••••••••
- Website quantgene.com
- Social LinkedIn X Facebook Instagram
- Legal Name Quantgene Inc
- Total Equity Funding$12.13M (USD)
in 3 rounds
- Latest Funding Round$6M (USD), Series B
Feb 2021
- Investors
Products & Services of Qantgene
Qantgene offers a comprehensive portfolio of products and services, including Qx, Genomic Tumor Profiling, and Qx Plus.
Platform for early cancer detection using genomics and intelligence.
Service for tumor analysis to improve cancer care outcomes.
Combines genomics with imaging for advanced cancer detection.
Funding Insights of Qantgene
Qantgene has successfully raised a total of $12.13M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $6 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.13M
- Total Rounds 3
- Last Round Series B — $6M
- First Round $980,000
(Jan 2017)
- Investors Count 1
All 3 funding rounds of Qantgene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2021 | $6M | Series B | – | Vikor Scientific | – |
| Oct 2017 | $5.15M | Series A | – | – | – |
| Jan 2017 | $980,000 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Qantgene
Qantgene has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Vikor Scientific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provides rapid molecular diagnostics and testing for pathogens in healthcare settings. | 2018 | vikorscientific.com | Charleston, United States |
Investor details for Qantgene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Qantgene
8 people are tracked at Qantgene (3 in leadership, 5 in team).
| Name | Role | Group |
|---|---|---|
Johannes Bhakdi | Founder & CEO | Leadership |
Jennifer Freiling | VP, Marketing & Commercial Operations | Leadership |
Ilia Ichetovkin | Chief Science Officer | Leadership |
Nivedha M. | Product Manager- Clinical | Team |
Michael Walkup | East Coast Operations/account Manager | Team |
Timothy Mohn | Cloud & Technology Lead | Team |
Nicole Groenke | Data Scientist | Team |
Silvia Gonzalez | Sr. Operations And Project Manager/executive Support | Team |
Complete people profiles for Qantgene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Qantgene
3 dated milestones of Qantgene across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Qantgene is founded.
- Funding First funding round of $980K.
- Funding Latest funding round, Series B, of $6.0M.
Competitors of Qantgene
Qantgene has 3 listed competitors in our database, 3 of them funded. They include GRAIL, Color and Earli.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| color.com | 2013 | Burlingame, United States | $491.44M | 687 | Cancer care is delivered through a virtual clinic by Color. | |
| earli.com | 2018 | San Francisco, United States | $40M | 38 | Early cancer detection tests are developed using synthetic biomarkers. |
Detailed competitors of Qantgene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Qantgene (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Qantgene
Complete news archive for Qantgene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Qantgene
Qantgene was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Qantgene is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Qantgene is a funded company, having raised a total of $12.13M across 3 funding rounds to date. The company's 1st funding round was a Seed of $980K, raised on Jan 2017.
Qantgene was founded in 2015 and is based in Berkeley, United States, within the biotechnology sector. Blood tests for cancer screening and early disease detection are developed and provided. The GRIFFIN Deep Genomics platform is employed, integrating precision sequencing, software, and AI to analyze cell-free DNA fragments. Operations focus on profiling genetic material to support diagnostic applications in healthcare.
Qantgene offers Qx, Genomic Tumor Profiling, and Qx Plus.
Qantgene has 1 investor. Key investors include Vikor Scientific.
Qantgene operates through Quantgene Inc.